BioSpace News Archive

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the second quarter of 2023.

Senti Biosciences, Inc., a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, reported financial results for the second quarter of 2023.

Schrödinger, Inc. reported that on August 9, 2023, the company granted a non-statutory stock option to purchase 90,000 shares of the company’s common stock and restricted stock units with respect to 15,000 shares of the company’s common stock to the company’s newly appointed chief medical officer, Margaret Dugan, M.D. As previously announced, Dr. Dugan joined the company on July 31, 2023.

Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate and clinical updates.

Zumutor Biologics Inc “Zumutor”, a Boston based biopharmaceutical company focused on developing unique novel therapeutics in immuno-oncology (I-O) today announces that the US Food and Drug Administration (FDA) has granted the company’s Investigational New Drug (IND) application for the novel drug ZM008 to initiate a Phase 1, first-in-human, clinical study for the treatment of multiple solid cancers.

Annexin Pharmaceuticals AB announces that an independent evaluation of potential signals of effect has been carried out in the company’s Phase 2-study in retinal vein occlusion with the investigational new drug ANXV.

Plus Therapeutics, Inc. reported positive data from the ReSPECT-LM clinical study evaluating the Company’s lead radiotherapeutic, rhenium obisbemeda, for the treatment of leptomeningeal metastases at the Society for Neuro Oncology /American Society of Clinical Oncology Central Nervous System Cancer Conference taking place August 10-12, 2023 in San Francisco, California.

HCW Biologics Inc. reported financial results and recent business highlights for its second quarter ended June 30, 2023.

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate activities.

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.